Download by
Scanning QR Code
No Stock Yet
Laimei Pharmaceutical (300006.SZ) plans a simplified procedure to raise no more than 300 million yuan
According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) announced that the board of directors of the company requested the shareholders' meeting to authorize the board of directors to fully handle matters relating to the issuance of shares to specific targets through simplified procedures. The authorization period is from the date of approval of the 2022 Annual General Meeting of Shareholders to the date of the 2023 Annual General Meeting of Shareholders. The issuance price is not less than 80% of the average stock transaction price for the 20 trading days prior to the pricing benchmark date. The total amount of capital raised in this issue does not exceed 300 million yuan and does not exceed 20% of net assets at the end of the last year.
Laimei Pharmaceutical (300006.SZ): Intended to request that the board of directors be authorized to issue shares to specific targets through simplified procedures
Gelonhui March 17 丨 Laimei Pharmaceutical (300006.SZ) announced that according to strategic development needs, in order to further enhance the company's core competitiveness and level of technological innovation in the pharmaceutical industry and better achieve the company's future development strategic goals, according to relevant regulations, the 28th meeting of the fifth board of directors of the company held on March 16, 2023 deliberated and passed the “Proposal on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Handle Issuance of Shares to Specific Targets Using Simple Procedures”, agreeing that the company's board of directors request the shareholders' meeting to authorize the board of directors to issue shares to specific targets using simple procedures Matters relating to stocks, licensing
Laimei Pharmaceutical (300006.SZ) announced its 2022 annual results, with a net loss of 687.091 million yuan, a narrowing of 31.65%
According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) released its 2022 annual report. The company's revenue was 885 million yuan, a decrease of 27.80% over the previous year. The net loss attributable to shareholders of listed companies was 687.091 million yuan, a year-on-year decrease of 31.65%. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was $115 million, a year-on-year decrease of 16.43%. The basic loss per share was $0.0651. The loss in performance in 2022 was mainly affected by a combination of factors such as the national collection policy and continued maintenance of large R&D investment. Influenced by national collection policies
Laimei Pharmaceutical (30006.SZ) is forecasting losses. The net loss for 2022 is expected to be 55 million yuan to 75 million yuan
According to the Zhitong Finance App, Laimei Pharmaceutical (30006.SZ) disclosed its 2022 annual performance forecast. The company expects a net loss of 55 million yuan to 75 million yuan to shareholders of listed companies in 2022, and a net loss of 100 million yuan to 120 million yuan after deducting non-recurring profit and loss. According to the announcement, due to the influence of the collection policy, the sales volume and price of the company's esomeprazole enteric capsules and other varieties declined further; during the reporting period, due to the epidemic, the number of non-COVID-related hospitalized patients decreased, which also had a certain impact on the delivery and sales of the company's related products. Overall, sales revenue during the reporting period fell by about 3 percent year-on-year
Laimei Pharmaceutical (300006.SZ): Drug Supplement Application Approval Notice for Triprorelin Acetate Injection
Glonhui, January 4, 丨 Laimei Pharmaceutical (300006.SZ) announced that recently, the company received the “Drug Supplement Application Approval Notice” for triprorelin acetate injection with specifications of 1ml: 0.1 mg, approved and issued by the Drug Administration. After review, the application for this product met the relevant requirements for drug registration, and it was agreed to approve the change of the marketing license holder of this product from “Hainan Shuangcheng Pharmaceutical Co., Ltd. (address: No. 16, Xingguo Road, Xiuying District, Haikou City)” to “Chongqing Laimei Pharmaceutical Co., Ltd. (address: No. 99, Yuma Road, Nan'an District, Chongqing)”. The drug approval number remained unchanged. Transferring drugs
Lummy Pharma Unit Gets Regulatory Nod in China for Liver Cirrhosis Drug
04:34 AM EST, 01/02/2023 (MT Newswires) -- Chongqing Laimei Longyu Pharmaceutical, a unit of Chongqing Lummy Pharmaceutical (SHE:300006), obtained approval from China's National Medical Products Admin
Laimei Pharmaceutical (300006.SZ): Application for marketing of the chemical ingredient teribapressin acetate approved
According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of the company, received the approval and issuance of the “Chemical Ingredient Drug Marketing Application Approval Notice” (acceptance number: CYHS2060492) for telibapressin acetate with a specification of 30g/piece from the China Drug Administration. According to reports, the raw material of teripressin acetate is used in the production of injectable teribapressin preparations. Telivapressin is a synthetic vasopressin analog. It is a vasoconstrictor drug among vasoactive drugs. It is mainly used for cirrhosis and varicose veins
Laimei Pharmaceutical (300006.SZ): The subsidiary received 55.19 million yuan in special funding for industry support in 2021
Gelonhui December 29 丨 Laimei Pharmaceutical (300006.SZ) announced that the company's holding subsidiary, Tibet Laimei Deji Pharmaceutical Co., Ltd., in accordance with the relevant provisions of the “Lhasa Economic and Technological Development Zone's 1+N Policy Implementation Opinions on Further Promoting High-Quality Industrial Development”, recently received special funds for 2021 from the Management Committee of the Tibet Lhasa Economic and Technological Development Zone, totaling 55.19 million yuan, accounting for 54.90% of the absolute value of the company's most recent audited net profit.
Zhongheng Group (600252.SH): Yaoyun Pharmaceutical will increase Chengdu Jinxing's capital by about 113 million yuan
Glonghui November 15 丨 Zhongheng Group (600252.SH) announced that recently, the company's holding subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. (“Laimei Pharmaceutical”) and its holding subsidiary Chengdu Jinxing Health Pharmaceutical Co., Ltd. (“Chengdu Jinxing”, “Target Company”), Chengdu Jinxing Minority Shareholder Sanum-Kehlbeck GmbH & Co.kg (“Shanum Germany”) and Chengdu Yaoyun Pharmaceutical Technology Co., Ltd. (“Yaoyun Pharmaceutical”) recently announced that the “Chengdu Jinxing Health Pharmaceutical Co., Ltd. Capital Increase and Subscription Agreement” (“originally intended to sign an agreement”) ”) Relevant terms
300006.SZ posted a net loss of 37.373 million yuan for the first three quarters.
Zhitong Financial APP News, Laimei Pharmaceutical (300006.SZ) released the third quarter report of 2022, the company's operating income in the first three quarters was 671 million yuan, down 24.77% from the same period last year. The net loss attributable to the shareholders of the listed company is 37.373 million yuan. The net loss after deducting non-recurring profit and loss belonging to the shareholders of the listed company is 70.0773 million yuan. The basic earnings per share is 0.33 yuan.
Loading...
No Stock Yet